• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why SentinelOne Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket

    12/6/23 8:32:03 AM ET
    $ACRS
    $ALLR
    $ASAN
    $ASPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRS alert in real time by email

    Shares of SentinelOne, Inc. (NYSE:S) rose sharply in pre-market trading after the company reported stronger-than-expected results for its third quarter and raised its annual revenue outlook.

    SentinelOne reported third-quarter revenue of $164.2 million, beating the analyst consensus estimate of $156.09 million. The company also reported an adjusted loss of 3 cents per share, beating the analyst consensus estimate of a loss of 8 cents per share, according to Benzinga Pro.

    The company raised the full-year 2024 revenue outlook from $605 million to $616 million.

    SentinelOne shares gained 18.6% to $23.71 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Clean Earth Acquisitions Corp. (NASDAQ:CLIN) shares gained 105.5% to $12.64 in pre-market trading after falling over 3% on Tuesday.
    • Greenbrook TMS Inc. (NASDAQ:GBNH) shares rose 78.7% to $0.4109 in pre-market trading after the company announced it raised $2.5 million in debt financing.
    • Dune Acquisition Corporation (NASDAQ:DUNE) rose 23.8% to $6.08 in pre-market trading after dipping over 15% on Tuesday.
    • Bit Brother Limited (NASDAQ:BETS) gained 23.5% to $0.0414 in pre-market trading. Bit Brother shares fell over 51% on Tuesday after the company announced the pricing of a $12 million registered direct offering.
    • Aclaris Therapeutics, Inc. (NASDAQ:ACRS) shares rose 19.6% to $1.18 in pre-market trading. Aclaris Therapeutics announced exclusive patent license agreement with Sun Pharma for rights of deuruxolitinib.
    • Meiwu Technology Company Limited (NASDAQ:WNW) shares surged 17.1% to $0.0937 in pre-market trading after gaining 11% on Tuesday.
    • Phio Pharmaceuticals Corp. (NASDAQ:PHIO) shares rose 17% to $1.31 in pre-market trading.
    • Mobiv Acquisition Corp (NASDAQ:MOBV) gained 16.4% to $5.82 in pre-market trading after gaining 5% on Tuesday.
    • Aspen Aerogels, Inc. (NYSE:ASPN) shares climbed 12.7% to $12.00 in pre-market trading. Aspen Aerogels reported additional EV Thermal barrier commercial award and issued an update on U.S. Department of Energy loan application status.

    Losers

    • ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) dipped 28.6% to $1.10 in pre-market trading after reporting a proposed public offering of common shares.
    • NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) shares fell 16.7% to $0.94 in pre-market trading after declining 24% on Tuesday. The company announced that it met its primary safety, tolerability and secondary clinical efficacy endpoints in its Phase 2b PARADIGM Trial of PrimeC in ALS.
    • Yext, Inc. (NYSE:YEXT) shares fell 15.6% to $5.92 in pre-market trading after the company reported third-quarter financial results and issued guidance.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) shares fell 13.7% to $0.50 in pre-market trading. Allarity recently announced initial results from its ongoing Phase 2 clinical trial evaluating the efficacy of stenoparib in women with advanced ovarian cancer.
    • Asana, Inc. (NYSE:ASAN) shares fell 13.4% to $20.19 in pre-market trading. Asana posted upbeat results for its third quarter and issued a strong forecast for FY24.
    • Box, Inc. (NYSE:BOX) fell 13% to $23.22 in pre-market trading after the company reported worse-than-expected third-quarter financial results and issued FY24 guidance below estimates.
    • Abits Group Inc. (NASDAQ:ABTS) shares fell 12% to $1.10 in pre-market trading after jumping 19% on Tuesday.
    • Nxu, Inc. (NASDAQ:NXU) fell 11.8% to $0.0225 in pre-market trading after declining more than 6% on Tuesday. NXU named Sarah Wyant as interim CFO, succeeding Apoorv Dwivedi.
    • Better Choice Company Inc. (NYSE:BTTR) fell 11.3% to $0.3236 in pre-market trading after gaining over 5% on Tuesday.
    • Janover Inc. (NASDAQ:JNVR) fell 8.1% to $1.49 in pre-market after surging 38% on Tuesday.

     

    Now Read This: Campbell Soup, SentinelOne And 3 Stocks To Watch Heading Into Wednesday

    Get the next $ACRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS
    $ALLR
    $ASAN
    $ASPN

    CompanyDatePrice TargetRatingAnalyst
    Aclaris Therapeutics Inc.
    $ACRS
    4/16/2026$10.00Outperform
    Oppenheimer
    Asana Inc.
    $ASAN
    4/14/2026$7.00Overweight → Neutral
    Piper Sandler
    Asana Inc.
    $ASAN
    4/1/2026$7.00Underperform → Sector Perform
    RBC Capital Mkts
    Box Inc.
    $BOX
    3/23/2026Outperform → Mkt Perform
    William Blair
    Yext Inc.
    $YEXT
    3/11/2026$6.00Buy → Neutral
    Roth Capital
    SentinelOne Inc.
    $S
    3/3/2026$13.00Equal Weight
    Wells Fargo
    Asana Inc.
    $ASAN
    1/15/2026$16.00Neutral → Buy
    Citigroup
    SentinelOne Inc.
    $S
    1/5/2026$17.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ACRS
    $ALLR
    $ASAN
    $ASPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer initiated coverage on Aclaris Therapeutics with a new price target

    Oppenheimer initiated coverage of Aclaris Therapeutics with a rating of Outperform and set a new price target of $10.00

    4/16/26 8:02:28 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Asana downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Asana from Overweight to Neutral and set a new price target of $7.00

    4/14/26 8:14:22 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    Asana upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Asana from Underperform to Sector Perform and set a new price target of $7.00

    4/1/26 8:10:23 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $ACRS
    $ALLR
    $ASAN
    $ASPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aspen Aerogels, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call

    NORTHBOROUGH, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE:ASPN) ("Aspen" or the "Company") today announced that Don Young, President & Chief Executive Officer, and Grant Thoele, Chief Financial Officer & Treasurer, expect to discuss the Company's financial results for the first quarter ended March 31, 2026, during a conference call scheduled for Thursday, May 7, 2026, at 8:30 a.m. ET. The Company also expects to release its quarterly financial results before the market opens on Thursday, May 7, 2026. Shareholders and other interested parties may participate in the conference call by dialing +1 (833) 461-5787 (domestic) or +1 (585) 542-9983 (international) and ente

    4/23/26 8:00:00 AM ET
    $ASPN
    RETAIL: Building Materials
    Consumer Discretionary

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

    Live Presentation and Q&A: Wednesday, April 29, 2026 12 PM EDTKing of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will provide an overview of the Company's INTASYL siRNA platform and discuss recent clinical progress and priorities, followed by a live Q&A.Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), mela

    4/23/26 7:00:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SentinelOne Wins a 2026 Google Cloud Partner of the Year Award

    Google NEXT — SentinelOne® (NYSE:S), the AI Security leader, today announced that it has been recognized as a 2026 Google Cloud Partner of the Year for Security: Google Threat Intelligence. The recognition comes as SentinelOne and Google Cloud deepen their collaboration on AI security innovation, runtime security, data sovereignty and threat intelligence. SentinelOne is an established Google Security partner with validated integrations across Google Security Operations (SecOps), Google Threat Intelligence, and Chrome Enterprise. In March 2026, at RSAC 2026, SentinelOne announced a significant expansion of the long standing partnership to deliver new solutions that integrate SentinelOne's

    4/22/26 9:00:00 AM ET
    $S
    Computer Software: Prepackaged Software
    Technology

    $ACRS
    $ALLR
    $ASAN
    $ASPN
    SEC Filings

    View All

    SEC Form DEFA14A filed by Aclaris Therapeutics Inc.

    DEFA14A - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    4/23/26 7:46:43 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Aclaris Therapeutics Inc.

    DEF 14A - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    4/23/26 7:45:36 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Allarity Therapeutics, Inc. (0001860657) (Filer)

    4/22/26 8:15:32 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ALLR
    $ASAN
    $ASPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Levie Aaron was granted 1,954 shares and covered exercise/tax liability with 791 shares, increasing direct ownership by 0.04% to 2,908,193 units (SEC Form 4)

    4 - BOX INC (0001372612) (Issuer)

    4/23/26 5:40:49 PM ET
    $BOX
    Computer Software: Prepackaged Software
    Technology

    Chief Financial Officer Smith Dylan C was granted 4,614 shares and covered exercise/tax liability with 2,316 shares, increasing direct ownership by 0.16% to 1,404,769 units (SEC Form 4)

    4 - BOX INC (0001372612) (Issuer)

    4/23/26 5:39:28 PM ET
    $BOX
    Computer Software: Prepackaged Software
    Technology

    Chief Operating Officer Nottebohm Olivia was granted 4,343 shares and covered exercise/tax liability with 2,180 shares, increasing direct ownership by 0.38% to 577,151 units (SEC Form 4)

    4 - BOX INC (0001372612) (Issuer)

    4/23/26 5:37:46 PM ET
    $BOX
    Computer Software: Prepackaged Software
    Technology

    $ACRS
    $ALLR
    $ASAN
    $ASPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, Pres. & CEO Bitterman Robert J bought $5,150 worth of shares (5,000 units at $1.03), increasing direct ownership by 2% to 291,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    1/2/26 4:05:06 PM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman, Pres. & CEO Bitterman Robert J bought $5,100 worth of shares (5,000 units at $1.02), increasing direct ownership by 2% to 286,421 units (SEC Form 4)

    4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

    12/29/25 8:10:21 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Peek Mark S bought $595,600 worth of shares (40,000 units at $14.89) (SEC Form 4)

    4 - SentinelOne, Inc. (0001583708) (Issuer)

    12/18/25 5:49:46 PM ET
    $S
    Computer Software: Prepackaged Software
    Technology

    $ACRS
    $ALLR
    $ASAN
    $ASPN
    Leadership Updates

    Live Leadership Updates

    View All

    SentinelOne Names Barry Padgett to President & Chief Operating Officer

    Promotion and expanded leadership role follow Padgett's successful tenure as SentinelOne's Chief Growth Officer and Interim Chief Financial Officer SentinelOne® (NYSE:S), the AI Security leader, today announced the appointment of Barry Padgett as President and Chief Operating Officer (COO), effective immediately. The promotion follows Padgett's successful tenure as the company's Chief Growth Officer and his recent role as interim Chief Financial Officer (CFO). This transition aligns with Sonalee Parekh officially starting her role as the company's new CFO, as announced earlier this month. In his elevated role as President and COO, Padgett will take on an expanded mandate, focusing on co

    3/24/26 8:30:00 AM ET
    $S
    Computer Software: Prepackaged Software
    Technology

    Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

    - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. "The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrou

    3/18/26 6:55:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SentinelOne Appoints Sonalee Parekh as Chief Financial Officer

    World's leading AI security firm ushers in next chapter of growth and profitability with new CFO SentinelOne (NYSE:S), the leader in AI-native cybersecurity, today announced the appointment of Sonalee Parekh as Chief Financial Officer, effective March 24, 2026. Ms. Parekh will oversee all aspects of the company's global financial operations, including FP&A, accounting, tax and treasury, internal audit, and investor relations. Barry Padgett will continue to serve as Interim CFO until Ms. Parekh's start date, leading the company's upcoming fiscal fourth quarter and full year 2026 earnings report and ensuring a seamless transition. Bringing more than 25 years of experience across public so

    3/3/26 4:05:00 PM ET
    $S
    Computer Software: Prepackaged Software
    Technology

    $ACRS
    $ALLR
    $ASAN
    $ASPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by SentinelOne Inc.

    SC 13D/A - SentinelOne, Inc. (0001583708) (Subject)

    12/12/24 6:30:27 PM ET
    $S
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by NeuroSense Therapeutics Ltd.

    SC 13G - NeuroSense Therapeutics Ltd. (0001875091) (Subject)

    12/9/24 4:00:18 PM ET
    $NRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/25/24 11:02:19 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ALLR
    $ASAN
    $ASPN
    Financials

    Live finance-specific insights

    View All

    Aspen Aerogels, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call

    NORTHBOROUGH, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Aspen Aerogels, Inc. (NYSE:ASPN) ("Aspen" or the "Company") today announced that Don Young, President & Chief Executive Officer, and Grant Thoele, Chief Financial Officer & Treasurer, expect to discuss the Company's financial results for the first quarter ended March 31, 2026, during a conference call scheduled for Thursday, May 7, 2026, at 8:30 a.m. ET. The Company also expects to release its quarterly financial results before the market opens on Thursday, May 7, 2026. Shareholders and other interested parties may participate in the conference call by dialing +1 (833) 461-5787 (domestic) or +1 (585) 542-9983 (international) and ente

    4/23/26 8:00:00 AM ET
    $ASPN
    RETAIL: Building Materials
    Consumer Discretionary

    Emerging AI-Driven Threats Prompt Renewed Focus on Enterprise Cybersecurity

    Issued on behalf of Quantum Secure Encryption Corp.VANCOUVER, BC, April 10, 2026 /CNW/ -- Equity-Insider.com News Commentary — Anthropic just proved that even the company building the most powerful offensive cyber tool ever created can't keep its own front door locked. A CMS misconfiguration exposed Claude Mythos, a frontier AI model that autonomously finds and exploits zero-day vulnerabilities across every major operating system and browser[1]. The Global X Cybersecurity ETF dropped 4.5% in a single session as Wall Street repriced the entire defensive stack overnight[2]. Anthropic responded with Project Glasswing: restricted Mythos Preview access for 40+ organizations to patch critical infr

    4/10/26 11:30:00 AM ET
    $AVGO
    $ESTC
    $GOOG
    Semiconductors
    Technology
    Computer Software: Prepackaged Software
    Computer Software: Programming Data Processing

    Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress

         Strengthened financial position through disciplined cost management, with a year-end 2025 cash position of $14.7 million and runway into mid-2028Received FDA Fast Track designation for stenoparib, enabling accelerated development in advanced ovarian cancerDurable clinical benefit observed in ongoing stenoparib ovarian cancer study, including patients treated for nearly 30 months, with new Phase 2 protocol implementedExpansion of stenoparib development beyond ovarian cancer with the launch of a VA-funded Phase 2 combination study in recurrent small cell lung cancer TARPON SPRINGS, Fla., March 31, 2026 – Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR), a Phase 2

    3/31/26 8:00:00 AM ET
    $ALLR
    Biotechnology: Pharmaceutical Preparations
    Health Care